News
IMCR
58.00
-0.80%
-0.47
Immunocore Holdings Price Target Maintained With a $92.00/Share by Guggenheim
Dow Jones · 2d ago
Guggenheim Reiterates Buy on Immunocore Hldgs, Maintains $92 Price Target
Benzinga · 2d ago
Weekly Report: what happened at IMCR last week (0415-0419)?
Weekly Report · 3d ago
Immunocore Holdings Becomes Oversold (IMCR)
NASDAQ · 04/15 20:58
Weekly Report: what happened at IMCR last week (0408-0412)?
Weekly Report · 04/15 09:20
Exelixis slips as Barclays downgrades on lack of catalysts
Barclays downgrades cancer drugmaker Exelixis on lack of catalysts. Lead asset cabozantinib faces a patent cliff, analyst says. Barclays sees better upside potential in other companies with similar pipelines. Exelxis shares traded lower on Thursday.
Seeking Alpha · 04/11 14:10
Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Imm immunocore Hldgs (NASDAQ:IMCR) is a late-stage biotechnology company. 8 analysts have published ratings on Immunocore hldgs in the last three months. The average price target is $81.0, with a 12-month price target of $90.00. The company is developing a new class of immunotherapies for the treatment of cancer.
Benzinga · 04/11 13:00
Immunocore Holdings Price Target Maintained With a $81.00/Share by Needham
Dow Jones · 04/11 10:50
Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
Benzinga · 04/11 10:40
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Immunocore Holdings (IMCR)
TipRanks · 04/11 10:10
Weekly Report: what happened at IMCR last week (0401-0405)?
Weekly Report · 04/08 09:22
Immunocore Says Selling Shareholders May Offer & Resell Up To 1.2M ADS, Pursuant To Prospectus Supplement
Imm immunocore Holdings plc filed a prospectus supplement to its effective registration statement with the U.S. Securities and Exchange Commission on April 5, 2024. The company filed to resale up to 1,220,063 American Depositary Shares of the Company.
Benzinga · 04/05 20:39
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?
Imm immunocore Holdings plc (NASDAQ:IMCR) has a fair value estimate of US$83.30. Analyst price target for IMCR is US$85.17, which is 2.2% above its current share price. We use a discounted cash flow model to estimate the intrinsic value of the company. The company is valued at a 25% discount to where it is currently valued at. Immunocore Holding's share price is currently around US$62.21. The model uses a 2-stage growth rate for the company's cash flows.
Simply Wall St · 04/05 14:02
Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)
TipRanks · 04/05 07:50
Analysts Offer Insights on Healthcare Companies: High Tide (HITI), Venus Concept (VERO) and Immunocore Holdings (IMCR)
Companies in the Healthcare sector have received a lot of coverage today. High Tide, Venus Concept and Immunocore Holdings have been reiterated by analysts today. Venus Concept has an analyst consensus of Hold while Immunocores Holdings has a Buy rating. The company's shares closed at $2.30 today.
TipRanks · 04/03 11:40
Weekly Report: what happened at IMCR last week (0325-0329)?
Weekly Report · 04/01 09:21
Weekly Report: what happened at IMCR last week (0318-0322)?
Weekly Report · 03/25 09:22
Immunocore Holdings Price Target Raised to $70.00/Share From $60.00 by JP Morgan
Dow Jones · 03/21 17:56
Immunocore Holdings Is Maintained at Overweight by JP Morgan
Dow Jones · 03/21 17:56
JP Morgan Maintains Overweight on Immunocore Hldgs, Raises Price Target to $70
Benzinga · 03/21 17:46
More
Webull provides a variety of real-time IMCR stock news. You can receive the latest news about Immunocore Holdings Plc through multiple platforms. This information may help you make smarter investment decisions.
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.